Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Non Operating Income (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Non Operating Income for 10 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 8323.08% year-over-year to $2.1 million, compared with a TTM value of $3.3 million through Sep 2025, down 16.18%, and an annual FY2024 reading of $4.8 million, up 22.23% over the prior year.
  • Non Operating Income was $2.1 million for Q3 2025 at Spero Therapeutics, up from $4000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.9 million in Q4 2023 and bottomed at -$2.6 million in Q1 2022.
  • Average Non Operating Income over 5 years is $185736.8, with a median of -$10000.0 recorded in 2023.
  • The sharpest move saw Non Operating Income crashed 8573.33% in 2022, then skyrocketed 43877.78% in 2023.
  • Year by year, Non Operating Income stood at -$78000.0 in 2021, then skyrocketed by 88.46% to -$9000.0 in 2022, then surged by 43877.78% to $3.9 million in 2023, then crashed by 71.4% to $1.1 million in 2024, then surged by 89.71% to $2.1 million in 2025.
  • Business Quant data shows Non Operating Income for SPRO at $2.1 million in Q3 2025, $4000.0 in Q2 2025, and $1000.0 in Q1 2025.